IDx-DR, an artificial intelligence system that detects diabetic retinopathy, is expanding to new healthcare settings since the FDA first cleared the AI system to go to market in April 2018, startup IDx of Coralville reports. IDx-DR is now in use in clinics focusing on endocrinology, internal medicine, diabetes education, community health, diagnostics labs and diabetes research groups. In October, the company announced a new agreement with ophthalmic device manufacturer TopCon to scale delivery for the IDx system for market.
